How to appeal a UnitedHealthcare eosinophilic esophagitis (eoe) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for eosinophilic esophagitis (eoe)

Cited policy: OptumRx Dupixent (Dupilumab) for EoE PA

Age >=1 yr and >=15 kg per Jan 2024 label. Histologic confirmation: peak >=15 eos/HPF on EGD biopsy from >=2 esophageal levels, on or off PPI. Inadequate response to 8-wk high-dose PPI OR PPI contraindicated. GI or allergist Rx. Reauth at 6 mo with symptom or histologic response.

How UnitedHealthcare denies eosinophilic esophagitis (eoe) — and how to counter it

Where UnitedHealthcare pushes back: 1) Step therapy: must fail 2 swallowed steroids first; 2) Must try elimination diet first; 3) Pediatric age cutoff outdated.

Counter-arguments that hold up: ACG 2020 + AGA/JTF 2020 list swallowed steroids, dietary elimination, and biologic as PARALLEL options — NO mandated sequence. LIBERTY-EoE-TREET NEJM 2022 — 60% histologic remission vs 5% placebo. EoE KIDS Lancet GH 2024 — Jan 25, 2024 expansion to ages 1+. Cite atopic-comorbidity (asthma/AD/CRSwNP/PN) Dupixent label-stacking when ≥1 coexists.

What UnitedHealthcare typically denies for eosinophilic esophagitis (eoe)

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For eosinophilic esophagitis (eoe), expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the eosinophilic esophagitis (eoe) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (EoE)
• Eohilia
• Fluticasone (off-label)
• Compounded budesonide
• High-dose PPI
• SFED

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.